Since the approval of deferasirox for patients with blood-transfusion-related iron overload by the FDA in 2005, >150,000 patient-years of exposure have occurred. However, nephrotoxicity is a common adverse effect of deferasirox therapy and the drug remains a medicine under additional monitoring status. Here, Díaz-García et al. review the clinical features, epidemiology and current understanding of the molecular mechanisms of deferasirox nephrotoxicity.
- Juan Daniel Díaz-García
- Angel Gallegos-Villalobos
- Alberto Ortiz
